PURPOSE: Statins have pleiotropic effects, including endothelial nitric oxide synthase (eNOS) upregulation and increased nitric oxide formation, which can be modulated by a genetic polymorphism in the promoter region of the eNOS gene (T-786C). Here, we report our investigation of whether this polymorphism modulates the effects of atorvastatin on the fluidity of erythrocyte membranes. METHODS: We genotyped 200 healthy subjects (males, 18-60 years of age) and then randomly selected 15 of these with the TT genotype and 15 with the CC genotype to receiveplacebo or atorvastatin (10 mg/day oral administration) for 14 days. Cell membrane fluidity was evaluated by electron paramagnetic resonance (EPR) and spin-labeling method. The EPR spectra were registered on a VARIAN-E4 spectrometer. Thiobarbituric acid-reactive species (TBA-RS) and plasma membrane cholesterol were determined in the erythrocytes. RESULTS:Atorvastatin reduced membrane fluidity in CC subjects (P < 0.05) but not in those with the TT genotype (P > 0.05). While no significant differences were found in plasma membrane cholesterol concentrations, higher TBA-RS concentrations were found in the CC subjects than in the TT subjects (P < 0.05). CONCLUSIONS: These findings suggest that a short treatment with atorvastatin is disadvantageous to subjects with the CC genotype for the T-786C polymorphism compared to those with TT genotype, at least in terms of the hemorheological properties of erythrocytes.
RCT Entities:
PURPOSE: Statins have pleiotropic effects, including endothelial nitric oxide synthase (eNOS) upregulation and increased nitric oxide formation, which can be modulated by a genetic polymorphism in the promoter region of the eNOS gene (T-786C). Here, we report our investigation of whether this polymorphism modulates the effects of atorvastatin on the fluidity of erythrocyte membranes. METHODS: We genotyped 200 healthy subjects (males, 18-60 years of age) and then randomly selected 15 of these with the TT genotype and 15 with the CC genotype to receive placebo or atorvastatin (10 mg/day oral administration) for 14 days. Cell membrane fluidity was evaluated by electron paramagnetic resonance (EPR) and spin-labeling method. The EPR spectra were registered on a VARIAN-E4 spectrometer. Thiobarbituric acid-reactive species (TBA-RS) and plasma membrane cholesterol were determined in the erythrocytes. RESULTS:Atorvastatin reduced membrane fluidity in CC subjects (P < 0.05) but not in those with the TT genotype (P > 0.05). While no significant differences were found in plasma membrane cholesterol concentrations, higher TBA-RS concentrations were found in the CC subjects than in the TT subjects (P < 0.05). CONCLUSIONS: These findings suggest that a short treatment with atorvastatin is disadvantageous to subjects with the CC genotype for the T-786C polymorphism compared to those with TT genotype, at least in terms of the hemorheological properties of erythrocytes.
Authors: Aline S Marroni; Ingrid F Metzger; Debora C Souza-Costa; Sabrina Nagassaki; Valeria C Sandrim; Ronan X Correa; Fabricio Rios-Santos; Jose E Tanus-Santos Journal: Nitric Oxide Date: 2005-05 Impact factor: 4.427
Authors: P S Silva; V Fontana; M R Luizon; R Lacchini; W A Silva; C Biagi; J E Tanus-Santos Journal: Eur J Clin Pharmacol Date: 2012-06-17 Impact factor: 2.953
Authors: Pamela S Silva; Vanessa Fontana; Ana C T Palei; Jonas T C Sertório; Celso Biagi; Jose Eduardo Tanus-Santos Journal: Eur J Clin Pharmacol Date: 2011-02-09 Impact factor: 2.953
Authors: Jaqueline J Muniz; Riccardo Lacchini; Jonas T C Sertório; Alceu A Jordão; Yuri T D A Nobre; Silvio Tucci; Antônio C P Martins; Jose E Tanus-Santos Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2013-05-19 Impact factor: 3.000